Previous 10 | Next 10 |
Stocks rebounded from recent weakness on Wednesday, as bargain hunting among beaten-down growth stocks pushed the major averages higher. The Nasdaq led the advance, climbing about 2% on the day. Travel stocks contributed to the upswing. An upbeat earnings report from Delta Air Lines raised ho...
B. Riley analyst Kalpit Patel downgraded Bicycle Therapeutics (BCYC -4.3%) to Neutral from Buy with a price target of $33, down from $62, after speaking to a physician-scientist focused on treating patients with genitourinary malignancies. The doctor was unsure of BT8009's regulatory path and...
Bicycle Therapeutics (BCYC -11.2%) has its price objective reduced by equities research analysts at Needham & Co. from $85 to $75 in a research note issued. The firm presently has a “Buy” rating on the stock. Needham & Co.’s target price would suggest a poten...
Bicycle Therapeutics plc (NASDAQ: BCYC) is down 30% after the biotech firm pioneering novel and differentiated therapeutics class based on its bicyclin peptide tech announced preliminary first phase results from the Phase 1/2 study of BT8009. BT8009 is a second-generation BTC target...
The following slide deck was published by Bicycle Therapeutics plc in conjunction with this event. For further details see: Bicycle Therapeutics presents at AACR Annual Meeting 2022 - Slideshow
Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto Holding (MSP) +21%. Axcella Health (AXLA) +16%. TScan Therapeutic...
Bicycle Therapeutics Limited plc (NASDAQ: BCYC) reported interim Phase I results from the Phase I/II trial of BT8009, a second generation BTC that targets Nectin-4. Results were presented on Sunday April 10th, at the 2022 American Association for Cancer Research Annual M...
The market yanked the rug out from under Bicycle Therapeutics (NASDAQ: BCYC) this morning in response to disappointing clinical trial results. Investors concerned about the company's experimental cancer treatments pushed the stock 29% lower as of 10:36 a.m. ET on Monday. Bicycle...
After announcing on Friday what it deemed promising results for bladder cancer candidate BT8009, leading to a rise in stock price, shares of Bicycle Therapeutics (NASDAQ:BCYC) are down 33% in premarket trading. Shares closed up ~24% on Friday. On that day, the company rele...
- 50% confirmed overall response rate, including one (13%) confirmed complete response in eight urothelial cancer patients dosed at 5.0mg/m 2 weekly - Median duration of response not yet reached in the 2.5mg/m 2 and 5.0mg/m 2 weekly cohorts; four of five responders in th...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced the acceptance of four abstracts for poster presentation at the European So...
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...